Supplementary File 1: Preclinical Data for Trop-2 ADC SHR-A1921 in Prostate Cancer

A 6.3 MB document authored by Binyu Wang and last updated on March 18, 2026, under a CC-BY-4.0 license. It details the preclinical development and evaluation of the novel antibody-drug conjugate SHR-A1921, including in vitro cytotoxicity assays, in vivo xenograft studies, and patient-derived organoid validation for prostate cancer.

Use Cases

• Analyzing preclinical efficacy metrics for Trop-2-targeted therapies based on the described in vitro and in vivo results.
• Training or validating predictive models for antibody-drug conjugate activity based on the described cytotoxicity and tumor-suppression data.
• Studying biomarker-target relationships in prostate cancer based on the described Trop-2 expression correlation with treatment response.

Strengths

• Document is 6.3 MB, suggesting detailed textual content.
• Includes data from multiple preclinical models: cell lines, xenografts, and patient-derived organoids.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect experimental bias inherent to the specific preclinical models described.

Provenance

Source

figshare, authored by Binyu Wang.

Collection Method

Data likely generated from laboratory experiments including cytotoxicity assays, xenograft models, and organoid cultures.

Time Range

Temporal coverage of the underlying experiments is not specified.

Freshness

Last updated 2026-03-18 10:14:39; freshness should be verified.

Geography

Spatial coverage is not specified.